16.63

3.61% +0.58

Lexeo Therapeutics Inc. (LXEO)

Overview News Price History Financials Discussions Forecast

Lexeo Therapeutics Inc. stock is currently priced at $16.63, with a 24-hour trading volume of 233.29K. It has seen a +3.61% increased in the last 24 hours and a +33.57% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $15.92 pivot point. If it approaches the $17.10 resistance level, significant changes may occur.

Previous Close:

$16.05

Open:

$16.01

24h Volume:

233.29K

Market Cap:

$547.88M

Revenue:

Net Income/Loss:

$-62.31M

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+7.57%

1M Performance:

+33.57%

6M Performance:

+30.74%

1Y Performance:

+0.00%

1D Range:

$15.85

$16.80

52W Range:

$9.32

$22.33

Lexeo Therapeutics Inc. Stock (LXEO) Company Profile

Name

Lexeo Therapeutics Inc.

Sector

Healthcare (1198)

Industry

Biotechnology (691)

Phone

212-547-9879

Address

345 Park Avenue South, 6th Floor, New York

Employee

Twitter

Next Earnings Date

Latest SEC Filings

LXEO's Discussions on Twitter

Lexeo Therapeutics Inc. Stock (LXEO) Latest News

Lexeo Therapeutics (LXEO) versus Its Peers Head-To-Head Contrast - Defense World

Defense World

Lexeo Therapeutics (NASDAQ:LXEO) Trading 4.9% Higher - MarketBeat

MarketBeat

Lexeo Therapeutics (NASDAQ:LXEO) Sees Unusually-High Trading Volume - MarketBeat

MarketBeat

Lexeo Therapeutics (NASDAQ:LXEO) & Repligen (NASDAQ:RGEN) Critical Analysis - Defense World

Defense World

Lexeo Therapeutics CEO sells shares worth over $66,000 By Investing.com - Investing.com Australia

Investing.com Australia

Wall Street Analysts Think Lexeo Therapeutics, Inc. (LXEO) Could Surge 57.82%: Read This Before Placing a Bet - MSN

MSN

Lexeo Therapeutics Inc. Stock (LXEO) Financials Data

Lexeo Therapeutics Inc. (LXEO) Net Income 2024

LXEO net income (TTM) was -$62.31 million for the quarter ending December 31, 2023.

Lexeo Therapeutics Inc. (LXEO) Earnings per Share 2024

LXEO earnings per share (TTM) was -$2.4445 for the quarter ending December 31, 2023.

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020 to treat ARVC caused by mutations in the PKP2 gene; LX2021 to treat DSP Cardiomyopathy associated with Cx43 deficiency; and LX2022 to treat HCM associated with mutations in the TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of POE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.